ERBB receptors and cancer: the complexity of targeted inhibitors
about
The application of the open pharmacological concepts triple store (Open PHACTS) to support drug discovery researchRecent advances of novel targeted therapy in non-small cell lung cancerInduction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasAutocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivationCopine-III interacts with ErbB2 and promotes tumor cell migrationCancer genome landscapesDesign, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainEphexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanismVRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancerEnhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactomeInhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceActivation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatasesIQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceMechanism of activation and inhibition of the HER4/ErbB4 kinaseIntegrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cellsErk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferationGAREM, a novel adaptor protein for growth factor receptor-bound protein 2, contributes to cellular transformation through the activation of extracellular signal-regulated kinase signalingEssential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activityA phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabMembrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cellsMammalian target of rapamycin: a central node of complex signaling cascadesDual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of MedulloblastomaProtein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transductionRegulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cellsStructure, evolution, and biology of the MUC4 mucinNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originQuercetin-induced ubiquitination and down-regulation of Her-2/neuA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursMetaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.Molecular mechanisms of peritoneal dissemination in gastric cancerCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsSoluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical RelevanceRecent developments in receptor tyrosine kinases targeted anticancer therapy
P2860
Q19845588-561E16D3-1B3A-4820-9A90-9DE115B407CCQ21092930-A47BF85B-F16B-4723-9913-C77014B045EFQ21144348-F59BA1F8-D58B-4355-A792-AF4CD300911CQ21195230-26821D5E-77E8-4BEE-8E26-71483FA557EAQ22001536-9375FFBE-2D24-445E-8383-C992C36F7BCEQ22242276-A3B4D64D-B9EE-4A52-BBBE-B2DC0240D5DCQ24293331-165F22BB-104E-460B-A489-8A9C67C30EE7Q24294233-3240BF89-CF56-4A04-84FE-0E5E2A6D27E9Q24294283-F42AAFCD-FA0E-4762-B831-F6A7BE41E976Q24294625-7A2D9A7B-40B0-4DA7-AABF-39F4E9FB39CDQ24301761-D3D82131-51DF-445C-9173-33CCDD32D667Q24306579-4E6977EA-013E-4867-83BC-248D914D2A7EQ24309891-3FDEF37D-751D-4EF1-B941-843155F318BFQ24310089-CA81BEB6-86C3-479E-9AA4-499798BF275BQ24311542-4EF7C0F2-E458-44F3-A6E5-0797E9D2F495Q24323390-B18FC40F-A115-408E-A20D-7949AC4CCD64Q24337649-43BC915C-4B9F-4595-9B35-EBA9FE840AABQ24537669-24233471-A425-44CA-B7DB-AA5EFA161BD1Q24546366-4C703B2B-47CD-4200-840F-C78F35D2B652Q24594725-7D8071C9-70B7-483D-A4BE-012FD971DA9DQ24601584-EC36758F-F211-4D91-BBE2-59F751584F3FQ24601702-09C46D25-4A3B-46A0-8800-3BFBCDCE2535Q24615472-DEA62E2F-7B36-43FC-85ED-223ECA09AE12Q24622527-C1BEE8C8-3CF7-4863-85C2-6B6CB6F3CF2BQ24623513-89A3111A-5AAB-45F5-975D-964F18BEEF9EQ24630950-BD8087F0-974E-4FDC-BB71-1398E1303BD5Q24630985-61F6D445-E704-4C6C-8C96-AB7B7A91483BQ24645217-4E0550D6-22F7-442B-9797-962138AAAC35Q24646978-BBC62F94-C68F-4C0B-9F1A-2FA73A31C143Q24647928-15DB7D99-48C2-47C1-BEC3-6EE2760B4B91Q24649935-726B4F92-176A-4716-B1DE-820F760DDC68Q24653999-CCB3689E-3302-44DB-A209-7EC50E4965FEQ25257542-B07F58A3-11D1-4860-895F-A863CFAE5DECQ26738538-E4D4748A-CF44-4E7F-87D0-F13E54ED62F2Q26740067-395C74D1-082A-46B9-9861-69149AFEF10AQ26744339-945CE2A5-3E1F-4B36-91F3-F093A3076670Q26745776-819EB5E5-4A32-4C25-8A4E-FA46EDEE091DQ26750719-12B5EC4C-67BA-4EEC-B355-70A6687F18F5Q26750970-3340BDCE-A654-48CA-A504-7BDCC3D67E63Q26751331-68ADB9C4-9A17-44EF-A33A-E478317DB324
P2860
ERBB receptors and cancer: the complexity of targeted inhibitors
description
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
im Mai 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: May 2005)
@en
wetenschappelijk artikel (gepubliceerd in 2005-05)
@nl
наукова стаття, опублікована в травні 2005
@uk
مقالة علمية (نشرت في مايو 2005)
@ar
name
ERBB receptors and cancer: the complexity of targeted inhibitors
@ast
ERBB receptors and cancer: the complexity of targeted inhibitors
@en
type
label
ERBB receptors and cancer: the complexity of targeted inhibitors
@ast
ERBB receptors and cancer: the complexity of targeted inhibitors
@en
prefLabel
ERBB receptors and cancer: the complexity of targeted inhibitors
@ast
ERBB receptors and cancer: the complexity of targeted inhibitors
@en
P2860
P3181
P356
P1476
ERBB receptors and cancer: the complexity of targeted inhibitors
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/NRC1609
P407
P577
2005-05-01T00:00:00Z
P5875
P6179
1049655893